Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryGenome-based Drug DiscoveryArtificial IntelligenceAI Drug Discovery

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737525

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737525

Artificial Intelligence in Omics Studies

PUBLISHED:
PAGES: 204 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Artificial Intelligence in Omics Studies Market to Reach US$4.5 Billion by 2030

The global market for Artificial Intelligence in Omics Studies estimated at US$913.5 Million in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 30.4% over the analysis period 2024-2030. AI Software, one of the segments analyzed in the report, is expected to record a 27.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the AI Services segment is estimated at 35.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$240.1 Million While China is Forecast to Grow at 28.9% CAGR

The Artificial Intelligence in Omics Studies market in the U.S. is estimated at US$240.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$679.7 Million by the year 2030 trailing a CAGR of 28.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.3% and 26.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 21.3% CAGR.

Global Artificial Intelligence in Omics Studies Market - Key Trends & Drivers Summarized

Why Is Artificial Intelligence Becoming Indispensable in the Evolution of Omics Research?

Artificial Intelligence (AI) is becoming a transformative force in omics studies-including genomics, transcriptomics, proteomics, metabolomics, and epigenomics-by enabling the analysis of vast, high-dimensional biological datasets that would otherwise be too complex and voluminous for traditional bioinformatics. Omics technologies generate massive quantities of multi-layered data, often requiring integrative and dynamic modeling approaches to uncover meaningful biological patterns, disease mechanisms, and therapeutic targets. AI, particularly machine learning (ML) and deep learning algorithms, is proving instrumental in identifying correlations, predicting gene-disease associations, modeling protein structures, and discovering biomarkers with far greater precision and scalability than conventional methods.

As life sciences shift toward personalized, systems-level medicine, the need for computational tools that can synthesize cross-omics data into actionable insights is becoming increasingly urgent. AI-driven platforms facilitate this by detecting hidden patterns, reducing dimensionality, and generating predictive models that are central to early diagnosis, drug response profiling, and disease progression monitoring. The convergence of omics research and AI is redefining how biomedical researchers, pharmaceutical companies, and precision medicine platforms develop hypotheses, accelerate discovery, and move closer to individualized treatment strategies.

How Are AI Models Enhancing Multi-Omics Integration and Predictive Accuracy?

The application of AI in omics is particularly transformative in multi-omics integration-combining data across genomic, transcriptomic, proteomic, and metabolomic layers to build holistic biological models. Machine learning algorithms, including support vector machines (SVMs), random forests, and deep neural networks, are enabling researchers to uncover latent associations between molecular signatures and complex phenotypes, such as cancer subtypes, neurodegenerative conditions, or rare diseases. AI models excel at managing data heterogeneity, missing values, and non-linear relationships-common challenges in multi-omics analytics.

Deep learning architectures, including convolutional neural networks (CNNs) and autoencoders, are being used to map genotype-to-phenotype links, predict protein folding (e.g., AlphaFold’s breakthrough in structural biology), and identify novel drug targets. Natural language processing (NLP) tools are extracting knowledge from unstructured biological literature to enrich omics annotations and hypotheses. Moreover, unsupervised learning is helping in clustering omics data for patient stratification and disease classification without prior labeling. These AI capabilities are empowering researchers to move from descriptive to predictive and even prescriptive analytics-creating dynamic, learning-based models of biology that can evolve with new data inputs.

Where Is AI in Omics Gaining Momentum and Which Fields Are Leading Applications?

AI applications in omics are gaining momentum in academic research, pharmaceutical R&D, precision oncology, rare disease diagnostics, and agricultural biotechnology. North America dominates the market, with leading institutions, genomics startups, and biopharma companies deploying AI to accelerate biomarker discovery, optimize trial designs, and develop companion diagnostics. Europe, particularly Germany, the U.K., and the Nordic countries, is seeing robust growth in AI-driven omics collaborations through EU-funded research frameworks. Meanwhile, Asia-Pacific-driven by China, Japan, and South Korea-is making strategic investments in AI genomics platforms to support national precision medicine initiatives and population-scale sequencing projects.

Cancer research remains the most active area, with AI models being applied to stratify tumors based on molecular subtypes, predict therapy response, and monitor resistance mechanisms using real-time omics data. In pharmacogenomics, AI is guiding drug metabolism studies by linking genotypes with drug response profiles. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are also gaining attention, where AI models analyze multi-omics and imaging data to uncover early biomarkers and progression patterns. In the agricultural space, AI-powered omics is enabling the development of climate-resilient crops, trait selection, and pathogen resistance optimization. This broad scope of application is catalyzing interdisciplinary collaborations and creating new commercialization pathways.

What Is Driving the Global Growth of Artificial Intelligence in Omics Studies?

The growth in artificial intelligence in omics studies is driven by several factors, including the explosion of high-throughput sequencing technologies, the affordability of multi-omics platforms, and the critical need for integrative analytics in personalized medicine. A key driver is the exponential increase in omics data generation from large-scale cohort studies, clinical trials, and population-wide genome initiatives. AI provides the computational infrastructure necessary to extract value from these datasets-turning them into actionable insights for diagnostics, therapeutics, and preventive healthcare.

Supportive policies and investments from governments, health systems, and private stakeholders are also fueling market expansion. Initiatives like the NIH’s All of Us Research Program, UK Biobank, and the China Precision Medicine initiative are deploying AI for genomic interpretation and risk modeling. Cloud-based bioinformatics platforms and AI-as-a-service models are further lowering barriers for adoption by research institutions and mid-sized biotech firms. Enhanced data sharing frameworks, coupled with advances in data anonymization and federated learning, are helping address privacy concerns while maximizing model robustness. As AI continues to reshape biomedical research, a critical question emerges: Can artificial intelligence enable a scalable, ethical, and clinically actionable integration of omics into mainstream healthcare and population-level disease prevention?

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Omics Studies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Software, Services); Technology (Sequencing, Epigenomics, Proteomics, Metabolomics, Other Technologies); Application (Oncology, Infectious Diseases, Neurology, Cardiovascular Diseases, Immunology, Other Applications); End-User (Academic & Research Institutes, Biopharmaceutical Company, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Agilent Technologies
  • Amazon Web Services
  • Anima Biotech
  • Antiverse
  • Atomwise
  • BenevolentAI
  • BGI Genomics
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Caris Life Sciences
  • Danaher Corporation
  • Deep Genomics
  • Exscientia
  • Fabric Genomics
  • GE Healthcare
  • GeneDx
  • Genetic Leap
  • Healx
  • Illumina Inc.
  • Insilico Medicine

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33463

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Artificial Intelligence in Omics Studies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI Algorithms Unlock New Biological Insights Across Genomics, Transcriptomics, and Proteomics
    • Machine Learning Accelerates Target Discovery in Complex Multi-Omics Datasets
    • AI-Powered Pattern Recognition Enables Early Disease Biomarker Identification in Omics Studies
    • Integration of AI with Next-Generation Sequencing Platforms Enhances Data Interpretation Speed
    • Personalized Medicine Strategies Leverage AI to Decode Omics Complexity in Clinical Contexts
    • Multi-Omics Data Fusion Using AI Enhances Predictive Modeling of Disease Progression
    • AI Platforms Support Scalable Annotation and Classification of Large Omics Repositories
    • Deep Learning Models Identify Non-Obvious Biological Relationships Within Omics Networks
    • Regulatory Interest in Explainable AI Tools Strengthens Clinical Use of Omics-Based Diagnostics
    • AI Automation in Omics Pipelines Reduces Time-to-Insight for Drug and Biomarker Discovery
    • Pharma and Biotech R&D Pipelines Embrace AI in Omics to Cut Costs and Improve Yield
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence in Omics Studies Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Omics Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biopharmaceutical Company by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biopharmaceutical Company by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Epigenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Epigenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 36: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 60: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 78: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 102: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!